Inhibition of human aldose and aldehyde reductases by non-steroidal anti-inflammatory drugs

Advances in Experimental Medicine and Biology

Volumn 463, Issue , 1999, Pages 493-499

  Ratliff, D M ^a   Martinez, F J ^a   Vander Jagt, T J ^a   Schimandle, C M ^a   Robinson, B ^a   Hunsaker, L A ^a   Vander Jagt, D L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PONALRESTAT; SORBINIL; SULINDAC; TOLRESTAT;

ARTICLE; CATARACT; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0033282007     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4735-8_62     Document Type: Article

References (18)

1. Prevention of cataract in diabetic rats by aspirin, paracetamol and ibuprofen
2. Inhibition of human lens aldose reductase by flavinoids, sulindac and indomethacin
3. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy
4. The inhibition of bovine lens aldose reductase by clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity
5. Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy
6. Naproxen: An aldose reductase inhibitor and potential anti-cataract agent
7. Relationship between aldose reductase inhibiting activity and anti-cataract action of various non-steroidal anti-inflammatory drugs
8. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: Two novel aldose reductase inhibitors
9. Role of aldose reductase in development of diabetes-associated complications
10. Differences in the susceptibility of various aldose reductases to inhibition
11. Reduction of basement membrane thickening in diabetic cat retina by sulindac
12. Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: Salicylate, indomethacin, oxyphen-butazone, sulindac
13. In vivo effectiveness of sulindac in sugar cataracts-the implication
14. Topical sulindac therapy in senile cataracts: Cataract-IV
15. Aldose reductase from human skeletal and heart muscle
16. Aldeyde and aldose reductases from human placenta
17. Reduction of trioses by NADPH-dependent aldo-keto reductases